EIF2AK3 and neoplasm: Furthermore, its detrimental off-target effects—promoting insulin resistance, cardiovascular disease, and neurodegeneration through chronic PERK activation (179, 180)—necessitate extremely careful therapeutic window definition and sophisticated tumor-targeted delivery strategies (e.g., PERK-activating nanoparticles) to avoid unacceptable systemic toxicity.